Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges